This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified member
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
English to Portuguese: Ketamine for Treatment-resistant Depression: Recent Developments and Clinical Applications General field: Medical Detailed field: Medical (general)
Source text - English Ketamine for Treatment-resistant Depression: Recent Developments and Clinical Applications
Approximately one-third of patients with major depressive disorder (MDD) do not respond to existing antidepressants, and those who do generally take weeks to months to achieve a significant effect.
There is a clear unmet need for rapidly acting and more efficacious treatments.
We will review recent developments in the study of ketamine, an old anaesthetic agent which has shown significant promise as a rapidly acting antidepressant in treatment-resistant patients with unipolar MDD, focusing on clinically important aspects such as dose, route of administration and duration of effect.
Additional evidence suggests ketamine may be efficacious in patients with bipolar depression, post-traumatic stress disorder and acute suicidal ideation.
We then discuss the safety of ketamine, in which most neuropsychiatric, neurocognitive and cardiovascular disturbances are short lasting; however, the long-term effects of ketamine are still unclear.
We finally conclude with important information about ketamine for primary and secondary physicians as evidence continues to emerge for its potential use in clinical settings, underscoring the need for further investigation of its effects.
Unipolar major depressive disorder (MDD) affects approximately 350 million people, making it the leading cause of disability worldwide, associated with harmful consequences onto the well-being of affected individuals and society.
Currently prescribed antidepressant treatments targeting the monoamine system only alleviate depressive symptoms in about half of the patients.
These rates become significantly lower in patients who had already failed to improve after two or more antidepressant treatments at adequate doses and duration (ie, treatment-resistant depression, TRD).
This results in unnecessary exposure to lengthy trials of ineffective medications.
Moreover, currently approved antidepressants targeting the monoamine system have a long onset in initiating response, typically 6–12 weeks.
Translation - Portuguese A cetamina para depressão resistente ao tratamento: avanços recentes e aplicações clínicas
Aproximadamente um terço dos pacientes com transtorno depressivo maior (TDM) não responde aos antidepressivos existentes, e aqueles que respondem geralmente levam entre semanas a meses para obterem um efeito significativo.
Há claramente uma necessidade não atendida de tratamentos com maior eficácia e ação mais rápida.
Analisaremos avanços recentes no estudo da cetamina, um agente anestésico antigo que se mostrou promissor como antidepressivo de ação rápida em pacientes com TDM unipolar resistentes ao tratamento, enfatizando aspectos clinicamente importantes como dose, via de administração e duração do efeito.
Dados adicionais sugerem que a cetamina talvez seja eficaz em pacientes com depressão bipolar, transtorno de estresse pós-traumático e ideação suicida aguda.
Em seguida, discutiremos a segurança da cetamina, na qual a maioria dos distúrbios neuropsiquiátricos, neurocognitivos e cardiovasculares são de curta duração. Contudo, os efeitos da cetamina em longo prazo ainda não foram definidos.
Finalmente, concluiremos fornecendo informações importantes sobre a cetamina para médicos de cuidados primários e secundários, conforme continuam a emergir dados para seu possível uso em cenários clínicos, destacando a necessidade de investigações adicionais sobre os seus efeitos.
O transtorno depressivo maior (TDM) unipolar afeta aproximadamente 350 milhões de pessoas, sendo a principal causa de incapacitação em todo o mundo, associada a consequências prejudiciais para o bem-estar dos indivíduos afetados e da sociedade.
Os tratamentos com os antidepressivos prescritos atualmente, que têm como alvo o sistema monoaminérgico, apenas aliviam os sintomas depressivos em cerca de metade dos pacientes.
Esses índices tornam-se significativamente mais baixos em pacientes que já não haviam obtido melhora após dois ou mais tratamentos com antidepressivos em doses e duração adequadas (ou seja, depressão resistente ao tratamento, DRT).
Isso leva à exposição desnecessária a estudos prolongados com medicações ineficazes.
Além disso, os antidepressivos aprovados atualmente, que têm como alvo o sistema monoaminérgico, apresentam um início de resposta tardio, normalmente entre seis e doze semanas.
fonte: http://www.medscape.com/viewarticle/862747
More
Less
Translation education
Other - Daniel Brilhante de Brito Translator Training Course
Experience
Years of experience: 33. Registered at ProZ.com: Feb 2015. Became a member: Oct 2015.
Credentials
English to Portuguese (Daniel Brilhante de Brito , verified)
Memberships
APTRAD - Associação de Profissionais de Tradução e de Interp
A native Brazilian Portuguese speaker, I am also proficient in English as I lived in the US as a child and have later obtained the Certificate of Proficiency in English from the University of Cambridge, among other qualifications.
I was a part-time translator for over 20 years until January 2015, when I started translating full-time.
I have had extensive experience with the English language not only in translation, but also in teaching and in the development and authorship of books and training materials for EFL/ESL students. My BS in Biological Sciences enables me to translate scientific materials in the field, including medical texts. I am familiar with military terminology and have translated different types of documents in that field as well.
I feel comfortable translating the following subjects: Life Sciences (Medicine, Dentistry, Nursing, Nutrition, Physical Education, Veterinary Medicine, Biology, Zoology, Botany, Ecology), Clinical Research, Healthcare, Education, Brazilian History, Military, Marketing, EHS, Human Resources, Law (general contracts), Journalism and general texts.
Member since Oct '15
Portfolio 
